Back to top
more

Avenue Therapeutics (ATXI)

(Delayed Data from NSDQ)

$2.19 USD

2.19
29,567

-0.10 (-4.37%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $2.18 -0.01 (-0.46%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Acer's (ACER) NDA for ACER-001 in UCD Gets FDA Acceptance

by Zacks Equity Research

The FDA accepts Acer's (ACER) NDA for ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders. A decision is due on Jun 5, 2022. Stock up.

CTI BioPharma (CTIC) Dips on Top-Line Data from COVID-19 Study

by Zacks Equity Research

CTI BioPharma (CTIC) posts top-line data from the PRE-VENT study evaluating pacritinib/standard of care as a treatment of severe COVID-19 infection.

Pacira (PCRX) Gets Notification of ANDA for Exparel, Stock Down

by Zacks Equity Research

Pacira (PCRX) receives a Paragraph IV Certification notice letter notifying that eVenus has submitted an ANDA for marketing a generic version of Exparel in the United States.

Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study

by Zacks Equity Research

Amneal's (AMRX) IPX-203 increases "Good On" time by 1.55 hours per dose versus immediate-release CD/LD in patients with Parkinson's disease.

Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion

by Zacks Equity Research

Trillium (TRIL) is set to be acquired by Pfizer for $2.3 billion or $18.50 per share. Stock shoots up.

What's in Store for Fulgent Genetics' (FLGT) Q1 Earnings?

by Zacks Equity Research

COVID-19 testing and NGS-based testing solutions are expected to have contributed to Fulgent Genetics' (FLGT) Q1 earnings.

BioRad (BIO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Growing demand for Polymerase Chain Reaction and Droplet Digital PCR products is expected to have contributed to BioRad's (BIO) Q1 growth.

What's in Store for Perrigo (PRGO) This Earnings Season?

by Zacks Equity Research

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

ResMed (RMD) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Improvement in demand for Mask and Other accessories along with rapid adoption of digital health solution is likely to have contributed to ResMed's (RMD) Q3 growth.

LabCorp (LH) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

With respect to LabCorp's (LH) COVID-19 testing services wing, although extensive vaccine rollouts are ongoing, the resurgence of the virus might have once again boosted testing demand in Q1.

Boston Scientific's (BSX) Watchman US Sale to Aid Q1 Earnings

by Zacks Equity Research

Within Boston Scientific's (BSX) coronary therapies, drug-eluting stents sale continue to be a challenge from a pricing standpoint in Q1.

Integra (IART) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

The acquisition of ACell, and faster recovery growth rate in Japan and China are likely to have helped recover Integra's first-quarter 2021 performance.

VITUS to Hurt Chemed (CHE) Q1 Earnings, Roto-Rooter to Aid

by Zacks Equity Research

The federal government's recent approach in terms of relaxing regulations, allowing broader use of telehealth, is likely to have helped in some sort of recovery of Chemed's (CHE) VITAS business in Q1.

Amedisys (AMED) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Growth in Home Health and Hospice along with recent innovation and acquisitions is expected to have contributed to Amedisys (AMED) top-line growth in Q1.

Molecular Tests to Drive Quest Diagnostics (DGX) Q1 Earnings

by Zacks Equity Research

Through the first quarter, Quest Diagnostics' (DGX) several significant strides in the field of COVID-19 diagnostic testing are expected to have contributed to the top line.

Avenue Therapeutics (ATXI) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Avenue Therapeutics (ATXI) has been struggling lately, but the selling pressure may be coming to an end soon

JAZZ's Xywav sNDA for Hypersomnia Gets FDA Priority Review

by Zacks Equity Research

JAZZ focuses on expanding label of its recently approved sleep drug, Xywav - a low sodium-formulation of Xyrem.

Demand for Nutrition Line to Drive Abbott (ABT) Q1 Earnings

by Zacks Equity Research

Two additional regulatory approvals in Europe are expected to have widened Abbott's (ABT) global Panbio customer base through Q1, contributing to the top line.

ChemoCentryx (CCXI) Reports Wider-Than-Expected Q3 Loss

by Zacks Equity Research

ChemoCentryx (CCXI) reports a wider-than-expected Q3 loss and misses sales estimates in the third quarter of 2020.

Catalyst's (CPRX) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2020.

Biotech Stock Roundup: REGN, GILD's Coronavirus News & Other Pipeline Updates

by Zacks Equity Research

Regeneron (REGN) and Gilead (GILD) continue to be in the spotlight on coronavirus-related updates.

Avenue Therapeutics' Pain Drug Gets Complete Response Letter

by Zacks Equity Research

Avenue Therapeutics' (ATXI) NDA seeking an approval for its pipeline candidate tramadol to treat postoperative pain gets a CRL from the FDA, based on potential safety concerns. Shares down.

Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2

by Zacks Equity Research

Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.

What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings?

by Zacks Equity Research

Avenue Therapeutics' (ATXI) sole pipeline candidate, tramadol, is under review. With lower clinical activities, operating expenses are likely to have declined during the second quarter.

Avenue Therapeutics, Inc. (ATXI) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.30, moving -1.9% from the previous trading session.